The new approval allows for the 2000mg loading dose to be administered as an IV push rather than a 30-minute IV infusion. The prescribing information for Trogarzo ® (ibalizumab-uiyk) has been updated ...
The approval was based on data from the phase 3 TMB-302 trial that evaluated Trogarzo 800mg administered via IV push once every 2 weeks. The Food and Drug Administration (FDA) has approved Trogarzo ® ...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
MONTREAL, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and ...
(RTTNews) - Theratechnologies Inc. (THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received FDA approval for the intravenous push mode ...
Are there any studies or guidelines available for the use of intravenous push antibiotics? Has anyone tried intravenous push (IVP)? During a recently conducted Consensus Development Conference on the ...
MONTREAL, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and ...
The label update follows FDA approval of the IV push maintenance dose in October 2022. With the new label, Trogarzo ® administration can now take only 90 seconds for the loading dose, as opposed to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback